Evidence map›Paper›PMID 42412118›Full record

ArticleCancer chemotherapy and pharmacology2026

Pharmacokinetics of asciminib in a patient with chronic myeloid leukemia undergoing maintenance hemodialysis.

Maiko Abumiya, Ko Abe, Atsushi Watanabe, Naoto Takahashi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maiko AbumiyaDepartment of Pharmacy, Akita University Hospital, Akita, Japan.
Ko AbeDepartment of Internal Medicine, Omagari Kosei Medical Center, Daisen, Japan.
Atsushi WatanabeDepartment of Internal Medicine, Omagari Kosei Medical Center, Daisen, Japan.
Naoto TakahashiDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita City, 010-8543, Akita, Japan. naotot@doc.med.akita-u.ac.jp.ORCID http://orcid.org/0000-0002-6758-3787

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asciminib (ASC) is a novel BCR::ABL1 tyrosine kinase inhibitor that binds to the ABL myristoyl pocket. Although dose adjustments for renal impairment are generally considered unnecessary, pharmacokinetic data for patients with end-stage renal disease or those on dialysis are limited. A 72-year-old man with chronic phase chronic myeloid leukemia undergoing maintenance hemodialysis for chronic renal failure was treated with ASC. Owing to cardiovascular risk, treatment was initiated at a reduced dose of 40 mg once daily. A major molecular response was achieved within 3 months without adverse events. Pharmacokinetic analysis revealed a delayed apparent T

Indexed as

Antineoplastic AgentsKidney Failure, ChronicLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsRenal DialysisAgedHumansMaleAntineoplastic AgentsProtein Kinase InhibitorsAsciminibChronic myeloid leukemiaHemodialysisIntra-individual variabilityPharmacokinetics

Identifiers

PMID42412118
PMCPMC13342300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.